These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

215 related items for PubMed ID: 20597027

  • 41. Impact of 5-HT₃ receptor antagonists on peripheral and central diseases.
    Fakhfouri G, Rahimian R, Ghia JE, Khan WI, Dehpour AR.
    Drug Discov Today; 2012 Jul; 17(13-14):741-7. PubMed ID: 22390946
    [Abstract] [Full Text] [Related]

  • 42.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 43.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 44.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 45.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 46.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 47.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 48. Chemokine receptor antagonist development.
    Garin A, Johnson Z, Hermant A, Beltran F, Ratinaud Y, Michel A, Krohn S, Gaudet M, Carboni S, Ji H, Missotten M, Leger O, Power C, Proudfoot A.
    Methods Mol Biol; 2013 Jul; 1013():67-92. PubMed ID: 23625494
    [Abstract] [Full Text] [Related]

  • 49. Broad spectrum chemokine inhibitors related to NR58-3.14.3.
    Grainger DJ, Reckless J, Fox DJ.
    Mini Rev Med Chem; 2005 Sep; 5(9):825-32. PubMed ID: 16178724
    [Abstract] [Full Text] [Related]

  • 50. Chemokines in pathology and medicine.
    Baggiolini M.
    J Intern Med; 2001 Aug; 250(2):91-104. PubMed ID: 11489059
    [Abstract] [Full Text] [Related]

  • 51. Natural product chemokine receptor antagonists: What mother nature has offered us?
    Yuan Y.
    Curr Top Med Chem; 2014 Aug; 14(13):1619-34. PubMed ID: 25159159
    [Abstract] [Full Text] [Related]

  • 52. Are we just learning the scales on the chemokine receptor pianos?
    Gilchrist A.
    Future Med Chem; 2012 May; 4(7):825-7. PubMed ID: 22571606
    [No Abstract] [Full Text] [Related]

  • 53. Viral leads for chemokine-modulatory drugs.
    Lindow M, Lüttichau HR, Schwartz TW.
    Trends Pharmacol Sci; 2003 Mar; 24(3):126-30. PubMed ID: 12628357
    [Abstract] [Full Text] [Related]

  • 54. Drug discovery targeting the chemokine system--where are we?
    Horuk R, Proudfoot AE.
    Front Biosci (Elite Ed); 2009 Jun 01; 1(1):209-19. PubMed ID: 19482638
    [Abstract] [Full Text] [Related]

  • 55. The development of anti-inflammatory drugs for infectious diseases.
    Garcia CC, Guabiraba R, Soriani FM, Teixeira MM.
    Discov Med; 2010 Dec 01; 10(55):479-88. PubMed ID: 21189219
    [Abstract] [Full Text] [Related]

  • 56. Chemokine receptors: multifaceted therapeutic targets.
    Proudfoot AE.
    Nat Rev Immunol; 2002 Feb 01; 2(2):106-15. PubMed ID: 11910892
    [Abstract] [Full Text] [Related]

  • 57. The attraction of chemokines as a target for specific anti-inflammatory therapy.
    Pease JE, Williams TJ.
    Br J Pharmacol; 2006 Jan 01; 147 Suppl 1(Suppl 1):S212-21. PubMed ID: 16402107
    [Abstract] [Full Text] [Related]

  • 58. "Chemokine receptors as therapeutic targets: Why aren't there more drugs?".
    Solari R, Pease JE, Begg M.
    Eur J Pharmacol; 2015 Jan 05; 746():363-7. PubMed ID: 25016087
    [Abstract] [Full Text] [Related]

  • 59. The strategy of blocking the chemokine system to combat disease.
    Proudfoot AE, Power CA, Wells TN.
    Immunol Rev; 2000 Oct 05; 177():246-56. PubMed ID: 11138781
    [Abstract] [Full Text] [Related]

  • 60. Strategies for chemokine antagonists as therapeutics.
    Proudfoot AE, Power CA, Rommel C, Wells TN.
    Semin Immunol; 2003 Feb 05; 15(1):57-65. PubMed ID: 12495641
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 11.